SCHEMBL5116452

SCHEMBL5116452

O=C(c1ccno1)N1CCC(O)(C#Cc2cccc(Cl)c2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 10/20 0.44
ENPP2 Q13822 1/20 0.40
ATXN2 Q99700 1/20 0.40
CYP46A1 Q9Y6A2 1/20 0.40
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 1/20 0.38
PTPN11 Q06124 1/20 0.38
CHRNB2 P17787 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA7 P36544 1/20 0.38
CHRNA4 P43681 1/20 0.38
USP2 O75604 1/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118736 0.83 PTPN11 (0.46) GRM5ENPP2ATXN2LMNAHTT
SCHEMBL5130079 0.83 ALDH1A1 (0.59) GRM5LMNAHPGDSMN1; SMN2ALDH1A1
SCHEMBL5125577 0.82 PKM (0.47) GRM5ENPP2ATXN2CYP46A1LMNA
SCHEMBL5129480 0.82 GRM5 (0.48) GRM5ENPP2ATXN2CYP46A1LMNA
SCHEMBL5126023 0.81 PTPN11 (0.45) GRM5LMNAHTTHPGDSMN1; SMN2
SCHEMBL5129768 0.81 GRM5 (0.54) GRM5ENPP2ATXN2ALDH1A1
SCHEMBL5130970 0.81 GRM5 (0.45) GRM5ENPP2ATXN2CYP46A1LMNA
SCHEMBL5118654 0.80 KMT2A (0.51) GRM5SMN1; SMN2ALDH1A1TSHRNPC1
SCHEMBL5129581 0.80 GRM5 (0.53) GRM5ENPP2ATXN2CYP46A1ALDH1A1
SCHEMBL5119724 0.79 MAPT (0.54) HPGDSMN1; SMN2ALDH1A1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269250-A1 Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists NOVARTIS AG (CH) 2008-10-30 US disclosed
EP-1856107-A1 PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS Novartis AG (CH) 2007-11-21 EP disclosed
WO-2006089700-A1 PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS NOVARTIS AG (CH) 2006-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269250-A1 Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists GRM5, GRIK5, GRM1 GRM5 1/4885ENPP2 1487/4885ATXN2 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.